ProMIS Neurosciences, Inc. (NASDAQ:PMN) Insider Buys $14,550.00 in Stock

ProMIS Neurosciences, Inc. (NASDAQ:PMN) insider Neil Cashman bought 15,000 shares of the stock in a transaction dated Monday, February 10th. The shares were acquired at an average price of $0.97 per share, with a total value of $14,550.00. Following the completion of the acquisition, the insider now directly owns 16,617 shares of the company’s stock, valued at approximately $16,118.49. The trade was a 927.64 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

ProMIS Neurosciences Stock Down 0.7 %

Shares of NASDAQ PMN opened at $0.95 on Friday. ProMIS Neurosciences, Inc. has a twelve month low of $0.87 and a twelve month high of $2.61. The firm has a market cap of $31.06 million, a P/E ratio of -9.50 and a beta of 0.56. The company has a 50 day moving average of $0.94 and a 200 day moving average of $1.08.

Hedge Funds Weigh In On ProMIS Neurosciences

A number of hedge funds have recently added to or reduced their stakes in the company. Great Point Partners LLC purchased a new position in ProMIS Neurosciences in the 3rd quarter worth approximately $3,488,000. Sphera Funds Management LTD. raised its holdings in ProMIS Neurosciences by 6.3% in the 3rd quarter. Sphera Funds Management LTD. now owns 1,929,297 shares of the company’s stock worth $2,412,000 after acquiring an additional 115,084 shares during the last quarter. Finally, Ally Bridge Group NY LLC raised its holdings in ProMIS Neurosciences by 50.3% in the 3rd quarter. Ally Bridge Group NY LLC now owns 1,592,605 shares of the company’s stock worth $1,991,000 after acquiring an additional 533,023 shares during the last quarter. 50.13% of the stock is currently owned by hedge funds and other institutional investors.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.